AstraZeneca’s Tagrisso (osimertinib) may not find widespread adoption in the adjuvant setting for non-small cell lung cancer (NSCLC), regardless of positive Phase III data, in the absence of a consensus on whether data suggesting a survival benefit is required.
The Phase III (NCT02511106) ADAURA study data was presented at the American Society of Clinical Oncology (ASCO) Virtual Meeting plenary session last month. Read more here.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
